Skip to main content

Company

Our mission is to develop clinically meaningful antibody suppression and enable effective therapies

Life-saving gene therapies are blocked by the body’s own defenses, leaving countless patients unable to access revolutionary treatments. As of 2024, the FDA has approved 36 gene therapies reflecting the rapid advancements in this field. In 2023 alone, seven gene therapies received approval. The pipeline is robust, with over 500 gene therapies in various stages of development, and senior FDA leadership anticipates that 10 or more new gene therapies will be approved annually by 2025. Effective immune suppression is now critical to successful gene delivery and maintaining long-term results.

“Too many people cannot receive a life changing gene therapy due to their own antibodies. We aim to bring the promise of gene therapy to every patient and make it last.”

Charles AskewCo-founder & President

Why it matters

Gene therapy is growing rapidly – suppression of neutralizing antibodies (Nabs) is critical to successful treatment.

1 in 10

people suffer from a rare genetic disease

30-60%

of patients are ineligible due to NAbs

Once

is the only shot patients have now at a cure